tbuckley/cabot-search huggingface dataset:
Analysis of prognostic factors in patients with adult T-cell leukemia/lymphoma
Authors: B. E. Beltran, D. Morales, P. Quiñones, R. Salas, J. Castillo
Journal: Journal of Clinical Oncology (2009)

8575 Background: Adult T-cell leukemia/lymphoma (ATLL) is associated with human T-cell lymphotropic virus type-I (HTLV-1) described in Southern Japan, Europe, Caribbean and South America. Risk-stratification tools for ATLL have not been adequately evaluated. This study attempts to define prognostic factors for patients with ATLL. Methods: A total of 102 cases from our Institution were collected between January 1997 and September 2008. Diagnosis was based on clinical history and histological findings consistent with ATLL and either positive HTLV-1 serology or evidence of HTLV-1 integration. Survival curves were estimated using the Kaplan-Meier method. Univariate and multivariate analyses were evaluated using log-rank and Cox regression tests, respectively. Results: Median age was 61 years with a female:male ratio of 1.15:1. Clinical types were acute (n=45), lymphomatous (n=43), cutaneous (n=10), smoldering (n=3) and chronic (n=1). Median OS for acute, lymphomatous, smoldering and cutaneous subtype were 2, 11, 17 and 39 months, respectively (log-rank 28.5, p&lt;0.00001). In the univariate analysis, presence of B symptoms, ECOG performance status 2, clinical stage II or higher, elevated LDH level and bone marrow (BM) involvement were independent factors for survival with p&lt;0.05. The IPI score was available in 92 patients; 13 (14%), 12 (13%), 29 (32%) and 38 (41%) patients were low, low-intermediate, high-intermediate and high-risk, respectively. Median OS by IPI risk group was 40, 13, 6 and 2 months, respectively (p&lt;0.005). The prognostic index for T-cell lymphoma (PIT) score was determined in 80 patients; 20 (25%), 17 (21%), 33 (41%) and 10 (13%) patients had scores of 0–1, 2, 3 and 4, respectively. Median OS by PIT risk group was 19, 5, 3 and 2 months, respectively (p&lt;0.005). In multivariate analysis, BM involvement and elevated LDH were significant for survival. Conclusions: This retrospective series represents the largest Latin-American experience on ATLL, which is a heterogeneous disease with distinct clinical features and outcomes. The IPI ant PIT scores, used for risk-stratification of aggressive B-cell and peripheral T-cell lymphomas, respectively, appear as good prognostic indicators for ATLL as well. Further research is needed to better risk-stratify this unique lymphoma. No significant financial relationships to disclose.
Prevalence and Clinical Significance of Portal Vein Thrombosis in Patients With Cirrhosis and Acute Decompensation
Authors: Yan Zhang, Bao-yan Xu, Xian-bo Wang, Xin Zheng, Yan Huang, Jinjun Chen, Zhong-ji Meng, Yan-hang Gao, Zhi-ping Qian, Feng Liu, Xiao-bo Lu, Yu Shi, Jia Shang, Hai Li, Shao-yang Wang, Shan Yin, Shu-ning Sun, Yi-Xin Hou, Yan Xiong, Jun Chen, Bei-ling Li, Qing Lei, Na Gao, Liu-juan Ji, Jing Li, Fang-rong Jie, Rui-hong Zhao, Jun-ping Liu, Tao-fa Lin, Liu-ying Chen, Wen-ting Tan, Qun Zhang, Cong-cong Zou, Ze-bing Huang, Xiu-hua Jiang, Sen Luo, Chun-yan Liu, Yu-yi Zhang, Tao Li, Hao-tang Ren, Shi-jin Wang, Guo-hong Deng, Shu-e Xiong, Xiao-xiao Liu, Chen Wang, Wei Yuan, Wen-yi Gu, Liang Qiao, Tong-yu Wang, Dan-dan Wu, Fu-chen Dong, Hai Li, Jing Hua
Journal: Clinical Gastroenterology and Hepatology (2020)
miRNA103a-3p in extracellur vesicles derived from IgE plus anti-IgE Ab activated human mast cells enhances IL-5 production in ILC2 in the presence of IL-33
Authors: Shota Toyoshima, Tomomi Sasaki-Sakamoto, Yusuke Kurosawa, Yasuhiro Gon, Chisei Ra, Kenji Matsumoto, Yoshimichi Okayama
Journal: Journal of Allergy and Clinical Immunology (2020)
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk
Authors: F. Ferrer-Marín, A. B. Arroyo, B. Bellosillo, E. J. Cuenca, L. Zamora, J. M. Hernández-Rivas, J. C. Hernández-Boluda, C. Fernandez-Rodriguez, E. Luño, C. García Hernandez, A. Kerguelen, D. V. Fiallo-Suárez, M. T. Gómez-Casares, R. Ayala, P. Vélez, C. Boqué, V. García-Gutierrez, B. Arrizabalaga, N. Estrada, R. Cifuentes, I. Arcas, A. M. de los Reyes-García, C. Besses, V. Vicente, A. Alvarez-Larrán, R. Teruel-Montoya, R. González-Conejero, C. Martínez
Journal: Leukemia (2020)
Renal biopsy cell cycle proliferation (CCP) score to predict adverse surgical pathology in renal cell carcinoma.
Authors: Jeffrey J. Tosoian, Adam S. Feldman, Madeline Abbott, Rohit Mehra, Placede Tiemeny, J. Stuart Wolf, Shulin Wu, Steven Stone, Chin-Lee Wu, Stephanie Daignault, Jeremy MG Taylor, Todd Matthew Morgan
Journal: Journal of Clinical Oncology (2020)

747 Background: The role of renal mass biopsy (RMB) in risk stratifying patients with renal cell carcinoma (RCC) is unclear. We sought to determine whether the cell cycle proliferation (CCP) score from RMB can improve risk stratification of localized RCC. Methods: We identified patients with RCC who underwent RMB and subsequent partial/radical nephrectomy from 2000-2014. We used multivariable logistic regression to determine the association of patient-level variables and biopsy CCP score with adverse surgical pathology (Fuhrman grade 3-4, pT stage≥3, papillary type II histology, or evidence of metastasis at surgery). Effect size was estimated with odds ratios (OR) and discriminative performance with AUC. Results: Overall, 94 of 202 patients (46%) had adverse surgical pathology. On multivariable analysis, CCP score &gt;0 was associated with 2.38-fold increased odds of adverse pathology (Table). Relative to the model omitting CCP score (AUC=0.70), the addition of CCP score as a continuous (AUC=0.731) or binary (AUC=0.730) variable yielded increased discriminative performance. Similar associations were observed in an analysis limited to patients with low-grade tumors on biopsy (bCCP: OR 2.44, p=0.024; cCCP: OR 1.57, p=0.11). In both models, increased lesion size on imaging was consistently associated with adverse pathology. Conclusions: Among patients with RCC, biopsy CCP score &gt;0 was independently associated with adverse pathology, suggesting this classifier provides prognostic information beyond conventional pathologic data. Biopsy CCP score could be used to better guide patient-specific management.[Table: see text]
Overall survival of black and white men with metastatic castrate-resistant prostate cancer: A retrospective analysis across 20 years in the largest healthcare trust in the United Kingdom.
Authors: Kenrick Ng, Peter Wilson, Katherine Mutsvangwa, Jonathan Shamash
Journal: Journal of Clinical Oncology (2020)

35 Background: Prostate cancer in Black (B) men has been associated with poorer outcomes than their White (W) counterparts. However, this perception has been derived from studies conducted predominantly in the localized prostate cancer setting, were based on data derived from clinical trials and usually conducted solely within the United States. Methods: We reviewed the outcomes of cases with metastatic castration resistant prostate cancer (mCRPC) treated at St Bartholomew’s Hospital – the UK's largest Healthcare Trust - between 1997-2016. Statistical analyses were conducted using Intercooled Stata 8.2 (State College, TX, USA). Results: We identified 425 cases of mCRPC in the 20 year period. A substantial minority of our patients, 103 (24%) were Black (B), and the remainder White (W). Characteristics were matched in age (73 years in both groups), proportion enrolled in clinical trials (33% in both groups) and median PSA (65.6,B vs 78,W, p=0.86), with a larger proportion of Black patients with a ECOG Performance Status ≥ 2 (19%,B vs 9%,W). In the total cohort analysis, the median Overall Survival (OS) was 25.5 months (B) vs 21.8 months (W), (Hazard Ratio, HR=0.81,p=0.08). For the subpopulation who received chemotherapy at some point of their treatment (n=306), survival was comparable in both groups (median OS 23.8 months, B vs 22.8 months, W, HR=0.97,p=0.82). Interestingly, there was a trend to prolonged survival in the Black population in those who only received hormone therapy (n=106) throughout their treatment course; 39.7 months (B) vs 17.1 months (W), HR=0.54, p=0.019. In a multivariate analysis for prognostic factors for survival from mCRPC therapy considering ethnicity (HR 0.81 p=0.08), time from diagnosis to castrate resistance (HR 1.02, p=0.136), presence of bone metastases at CRPC diagnosis (HR 1.89,p=0.001) – only bone metastases were significant. Conclusions: In the first set of real-world data in a study conducted outside the US, we demonstrate that Black patients do not do worse than White patients with mCRPC. The study suggests that there is a greater margin of benefit of hormone-based therapy in the Black subpopulation.
Association of Serum Folate Levels With Cardiovascular Mortality Among Adults With Rheumatoid Arthritis
Authors: Kalyani Sonawane, Yenan Zhu, Wenyaw Chan, David Aguilar, Ashish A. Deshmukh, Maria E. Suarez-Almazor
Journal: JAMA Network Open (2020)

Patients with rheumatoid arthritis (RA) are at high risk for cardiovascular (CV) mortality, attributed to chronic inflammation coupled with elevated circulatory homocysteine levels. Increasing the serum folate level reduces homocysteine, but the association of serum folate concentration with CV mortality in patients with RA has not been previously examined.To examine the association of serum folate concentration and CV mortality risk among patients with RA.A cohort study of the third National Health and Nutrition Examination Survey (1988-1994) and 2011 Linked Mortality File was performed. Adults aged 18 years or older with self-reported physician-diagnosed RA were included. Data analysis was performed between April 2019 and June 2019.Serum folate level.All-cause and CV mortality risk estimated using Cox proportional hazards models, adjusted for the complex survey design and patient characteristics, including demographic characteristics, body mass index, C-reactive protein level, smoking, RA medication use, and comorbid conditions.A total of 683 patients with RA (mean [SE] age, 55.9 [1.0] years; 225 [30.2%] men; 478 [87.0%] white) were classified into tertiles based on serum folate levels, as follows: tertile 1, folate levels less than 4.3 ng/mL (n = 239); tertile 2, folate levels 4.3 ng/mL to 8.2 ng/mL (n = 234); and tertile 3, folate levels greater than 8.2 ng/mL (n = 210). During a median (interquartile range) follow-up of 17.4 (10.0-19.4) years, a total of 392 all-cause deaths and 258 CV deaths occurred. Compared with tertile 1, patients in tertile 2 had lower all-cause mortality risk (hazard ratio [HR], 0.63; 95% CI, 0.47-0.85). The risk of CV mortality was lower among patients in tertile 2 (HR, 0.52; 95% CI, 0.30-0.92) and tertile 3 (HR, 0.44; 95% CI, 0.26-0.75) compared with those in tertile 1 (P for trend = .01). Findings for CV mortality were consistent in a sensitivity analysis that estimated 10-year risk; patients in tertile 2 (HR, 0.31; 95% CI, 0.17-0.57) and tertile 3 (HR, 0.39; 95% CI, 0.22-0.69) had lower CV mortality risk compared with those in tertile 1 (P for trend = .04).Among patients with RA, a serum folate level of at least 4.3 ng/mL was associated with lower CV mortality risk. Further research is needed to examine whether a causal relationship exists between serum folate and CV risk among patients with RA.
Pru p 9 and Ole e 6-like, two new Peach tree pollen allergens, can elicit respiratory symptoms in children
Authors: Laura Victorio Puche, Maria Somoza Alvarez, Jose Damian Lopez Sanchez, Maria Garrido-Arandia, Laura Martín-Pedraza, Paula Lopez, Diana Perez Alzate, Elisa Haroun-Diaz, Ana María Prieto-Moreno Pfeifer, Araceli Diaz Perales, M Teresa Villalba, Gabriela Canto Díez, Miguel Blanca
Journal: Journal of Allergy and Clinical Immunology (2020)
Exploration of 5-cyano-6-phenylpyrimidin derivatives containing an 1,2,3-triazole moiety as potent FAD-based LSD1 inhibitors
Authors: Liying Ma, Haojie Wang, Yinghua You, Chaoya Ma, Yuejiao Liu, Feifei Yang, Yichao Zheng, Hongmin Liu
Journal: Acta Pharmaceutica Sinica B (2020)

Histone lysine specific demethylase 1 (LSD1) has become a potential therapeutic target for the treatment of cancer. Discovery and develop novel and potent LSD1 inhibitors is a challenge, although several of them have already entered into clinical trials. Herein, for the first time, we reported the discovery of a series of 5-cyano-6-phenylpyrimidine derivatives as LSD1 inhibitors using flavin adenine dinucleotide (FAD) similarity-based designing strategy, of which compound 14q was finally identified to repress LSD1 with IC50 = 183 nmol/L. Docking analysis suggested that compound 14q fitted well into the FAD-binding pocket. Further mechanism studies showed that compound 14q may inhibit LSD1 activity competitively by occupying the FAD binding sites of LSD1 and inhibit cell migration and invasion by reversing epithelial to mesenchymal transition (EMT). Overall, these findings showed that compound 14q is a suitable candidate for further development of novel FAD similarity-based LSD1 inhibitors.
Methods of Calculating Low-Density Lipoprotein Cholesterol Level
Authors: William Virgil Brown
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Comprehensive genomic profiling (CGP) of metastatic castrate-sensitive prostate cancer (mCSPC) to reveal potential biomarkers and therapeutic targets.
Authors: Di Maria Jiang, Bryan Wong, Aaron Richard Hansen, Nazanin Fallah-Rad, Adrian G. Sacher, Tong Zhang, Shamini Selvarajah, Tracy Stockley, Philippe L. Bedard, Srikala S. Sridhar
Journal: Journal of Clinical Oncology (2020)

198 Background: Docetaxel and androgen receptor (AR) targeted agents have become standard options for mCSPC. CGP data is limited in mCSPC, however has the potential to guide treatment selection. We aimed to establish the feasibility of using CGP to characterize genomic alterations (GAs) in mCSPC. Methods: Patients with mCSPC were prospectively recruited at the Princess Margaret Cancer Centre to the OCTANE trial (NCT02906943), which aims to establish a genomically-characterized and clinically-annotated patient base that can be enrolled into specific research initiatives. Archival tumour specimens (after clinical testing completed) were profiled using next-generation sequencing (NGS) with a custom hybridization capture DNA-based panel (555 genes) or a targeted DNA/RNA amplicon panel (Oncomine Comprehensive Assay v3, 161 driver gene panel). GAs were classified according to the 2017 AMP/ASCO/CAP consensus recommendation. Clinical data were extracted from electronic health records. Results: Since 2016, 17/31 (55%) mCSPC patients who enrolled had sufficient tissue (15 from primary, 1 lymph node, 1 bone) for CGP. All had adenocarcinoma histology, most had high volume (76%) or de novo (71%) mCSPC. Median presenting PSA was 56 µg/L (range 8.4 – 1394). Patients received docetaxel (88%) or abiraterone (12%). Tier I/II GAs consistent with possible benefit from approved or investigational targeted therapies were identified in 14/17 patients (82%). AR pathway GAs (in 29%) were present regardless of prior androgen deprivation therapy or disease volume. DNA damage repair GAs (in 65%) included BRCA2, ATM, PALB2, MLH1/3, CDK12, FANCA, ERCC4, and SPOP. Other GAs involved the cell cycle, mTOR, EGFR, wnt, hedgehog, notch, and epigenetic pathways. Conclusions: In this small cohort, CGP was feasible in the setting of mCSPC for half of the patients. Potentially actionable GAs were identified in over 80% of patients tested. Pending confirmation from larger cohorts, these data support CGP in mCSPC prior to systemic therapy initiation, and highlight its potential role in future biomarker development and trial design in mCSPC.
Association between eicosanoids in exhaled breath condensate and type 2 immunological mediators in sputum from patients with asthma
Authors: Yuki Hoshino, Tomoyuki Soma, Yoshitaka Uchida, Hidetoshi Iemura, Erika Naito, Kazuki Katayama, Ryu Sekiya, Kazuyuki Nakagome, Makoto Nagata
Journal: Journal of Allergy and Clinical Immunology (2020)
Lower Blood Pressure in South Asia? Trial Evidence
Authors: Neil Poulter
Journal: New England Journal of Medicine (2020)

The report by Jafar et al.1 in this issue of the Journal suggests that a low-cost intervention, if scaled up, "might translate into substantial reductions in premature deaths and disability." This potential benefit arises from the reduction in systolic blood pressure shown in a cluster-randomized trial involving 2645 adults with hypertension from rural districts in Bangladesh, Pakistan, and Sri Lanka, who received an inexpensive multicomponent intervention or usual care. The multicomponent intervention included regular home visits from trained community health workers who monitored blood pressure and provided health education and counseling. In addition, local physicians were trained to follow a . . .
Corrigendum to An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45
Authors: V. Bjelic-Radisic, F. Cardoso, D. Cameron, E. Brain, K. Kuljanic, R.A. da Costa, T. Conroy, E.C. Inwald, S. Serpentini, M. Pinto, J. Weis, O. Morag, G. Lindviksmoen Astrup, K.A. Tomaszewski, K. Pogoda, P. Sinai, M. Sprangers, N. Aaronson, G. Velikova, E. Greimel, J. Arraras, A. Bottomley
Journal: Annals of Oncology (2020)

The authors regret that Dr Tomaszewski's name and affiliation were incorrectly given. These should be Tomaszewski KA of Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland. The authors would like to apologise for any inconvenience caused. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45Annals of OncologyVol. 31Issue 2PreviewThe European Organization for Research and Treatment of Cancer (EORTC) QLQ-BR23 was one of the first disease-specific questionnaires developed in 1996 to assess quality of life (QoL) in patients with breast cancer (BC). However, since 1996 major changes in BC treatment have occurred, requiring an update of the EORTC BC module. This study presents the results of the phase I–III update of the QLQ-BR23 questionnaire. Full-Text PDF Open Archive
Exhaled volatile organic compounds for better asthma control: could it be a future noninvasive adherence test?
Authors: Florence N. Schleich, Delphine Zanella, Jean-François Focant
Journal: European Respiratory Journal (2020)

<b>VOCs are surrogate markers for salbutamol and OCS use, which are part of the definition of poor asthma control. This suggests that VOCs are promising biomarkers that could possibly be used to detect poor adherence to inhaled therapy.</b>http://bit.ly/2SgE44R
Tolerance Development Following Oral Immunotherapy (OIT) in 1-3 Year Old Children with Peanut Allergy: Findings from the Immune Tolerance Network (ITN) IMPACT TRIAL
Authors: Stacie Jones, Edwin Kim, Kari Nadeau, Anna Nowak-Wegrzyn, Robert Wood, Hugh Sampson, Amy Scurlock, Sharon Chinthrajan, Jacqueline Johnson, Katharine Spain, Joy Laurienzo, David Larson, Marshall Plaut, Tielin Qin, Srinath Sanda, Michelle Sever, Lisa Wheatley, Don Whitehouse, Rachel Yan, A. Wesley Burks
Journal: Journal of Allergy and Clinical Immunology (2020)
Abstract 16755: Endothelin-1 and PAI-1 Produce Fibrotic Aortic Valve Stenosis
Authors: Phanicharan Sistla, Yi Chu, Robert M Brooks, Donald D Lund, Kathy A Zimmerman, Melissa K Kafa, Douglas E Vaughan, Pierre Paradis, Ernesto C Schiffrin, Robert M Weiss, Donald D Heistad
Journal: Circulation (2017)

Background: Studies in mice and humans have demonstrated associations between aortic valve stenosis (AVS) and two profibrotic molecules, endothelin-1 (ET-1) and plasminogen activator inhibitor-1 (P...
Number Eight in the Service of Diabetic Foot Ulcer Healing
Authors: Magnus Löndahl
Journal: Diabetes Care (2020)

In this issue of Diabetes Care , Frykberg et al. (1) further enhance the armamentarium of diabetic foot ulcer (DFU) treatment by publishing the outcome of a double-blinded, randomized, placebo-controlled study evaluating the effect of cyclical topical wound oxygen therapy.

The importance of oxygen in human physiology is not least marked by the 2019 Nobel Prize in Physiology awarded to William Kaelin Jr., Sir Peter Ratcliffe, and Gregg Semenza for their pioneering research into how human cells respond to changing oxygen levels. It is well established that chronic DFUs are not infrequently characterized by hypoxia, and in the microenvironment of these ulcers there exists a substantial imbalance between the supply of oxygen and the high energy demand of the healing (2). Treatment modalities such as hyperbaric oxygen therapy (HBOT) and topical oxygen therapies (TOT) have both been shown to increase vascular endothelial growth factor production and subsequently promote neovascularization (3–6). HBOT has been used in clinical practice as an adjunct to standard therapy for many years, although the outcomes of randomized controlled trials (RCT) are inconclusive (3,7–10). However, there is marked heterogeneity in the patient and ulcer inclusion criteria among these studies, and the latest high-quality RCT, showing a numerical difference in major amputations between HBOT and control groups, unfortunately recruited too few participants to reach statistical power (10). There are lessons from these trials also to be learned in the field of TOT (Fig. 1). As for HBOT, TOT is based …